ASH Annual Meeting

The efficacy and safety of naratuximab emtansine plus rituximab appear impressive for patients with B-cell non-Hodgkin lymphomas who are ineligible for stem cell transplant or chimeric antigen receptor T-cell therapy.

Undetectable minimal residual disease may be achieved with time-limited ublituximab and umbralisib added to ibrutinib in patients with chronic lymphocytic leukemia.

Phase 3 ZUMA-7 study results indicate that axicabtagene ciloleucel may achieve longer event-free survival compared with standard chemotherapy.

A CARTITUDE-1 meta-analysis data shows that ciltacabtagene autoleucel performs better than standard-of-care therapy in terms of survival and response rates in patients with triple-class relapsed/refractory multiple myeloma.

Results from the phase 2 IFM 2018-01 trial show positive safety and efficacy for the combination of daratumumab with ixazomib, lenalidomide, and dexamethasone.

Analysis shows that International Prognostic Scoring System score and the presence of a JAK2 mutation was linked to risk of thrombosis in patients with primary myelofibrosis. Investigators observed a benefit for ruxolitinib in patients.

Minimum residual disease can inform approaches to treatment of newly diagnosed multiple myeloma for patients receiving daratumumab plus carfilzomib, lenalidomide, and dexamethasone following autologous transplant.

Axicabtagene ciloleucel demonstrated a quality of life improvement in patients with large B-cell lymphoma as a second-line treatment compared with standard of care.

In a randomized phase 3 trial, acalabrutinib plus venetoclax versus obinutuzumab plus venetoclax will be investigated for efficacy and safety with a noninferiority design in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic leukemia.

Chemotherapy with the addition of eryaspase showed biological efficacy in reducing hypersensitivity reactions to asparaginase in patients with acute lymphoblastic leukemia.

Findings from the phase 3 ASCEMBL trial showed a consistent improvement in major molecular response rate and depth of response without any new or worsening adverse effects when treating with asciminib versus bosutinib in patients with chronic-phase chronic myeloid leukemia.

Real-world data on tisagenlecleucel in patients with relapsed/refractory B-cell lymphoma was consistent with the phase 2 JULIET trial, demonstrating favorable efficacy and safety.

Older patients with diffuse large B-cell lymphoma experienced improved progression-free survival, quality of life, and function after receiving ibrutinib plus rituximab and mini-CHOP.

Patients with late- and early-relapsed multiple myeloma receiving the combination of selinexor plus daratumumab, bortezomib, and dexamethasone showed promising efficacy and a manageable safety profile.

Patients with relapsed/refractory chronic lymphocytic leukemia experienced progression-free survival benefit with acalabrutinib versus the standard of care, and therapy was effective out to 3 years in the ASCEND trial.

Frontline ibrutinib and rituximab plus fludarabine, cyclophosphamide, and rituximab improved quality of life in patients with chronic lymphocytic leukemia; ibrutinib given continuously maintained the improved quality of life, and it did not decline over time.

Tisagenlecleucel showed similar efficacy outcomes and a more favorable safety profile in real-world data of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia versus the ELIANA trial.

The XVd regimen demonstrated comparable efficacy and safety in patients with multiple myeloma who had high-risk or standard-risk cytogenetic features.

In patients with cancer, anxiety and depression can influence how they view cancer clinical trials, which leads to low enrollment.

Patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome had higher mortality rates after being diagnosed with COVID-19 than those with COVID-19 who did not have cancer.

In patients with largely resistant CP-CML, ponatinib showed clinical activity when administered at the 45 mg compared with lower doses.

The use of isatuximab with the RVd regimen in the induction phase may improve minimal residual disease negativity rates in patients with multiple myeloma, phase 3 results show.

High antibody levels were observed in patients with acute myeloid leukemia and myelodysplastic syndrome who received the mRNA-1273 SARS CoV-2 vaccination.

No overlapping toxicities and a tolerable safety profile were seen with the addition of talquetamab to daratumumab in a population of patients with relapsed/refractory multiple myeloma.

In patients with relapsed or refractory marginal zone lymphoma, parsaclisib produced a clinical response.

Higher sustained MRD-negativity rates were observed among patients with transplant-eligible newly diagnosed multiple myeloma receiving D-VTd over VTd alone

Looking at frontline venetoclax based combinations shows promise for fit patients with CLL.

In an analysis of the phase 3 GLOW study, data showed promise for the use of ibrutinib/venetoclax in the frontline setting.

New results from the CAPTIVATE study demonstrated that treatment with ibrutinib and venetoclax in the first-line setting of patients with CLL continues to elicit durable responses to placebo.

Data from the phase 2 VISION trial showed that restarting treatment with the combination was feasible in a select group of patients who initially had undetectable MRD after 15 cycles of treatment.